Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- Author(s)
- Pardanani, A; Gotlib, J; Roberts, AW; Wadleigh, M; Sirhan, S; Kawashima, J; Maltzman, JA; Shao, L; Gupta, V; Tefferi, A;
- Details
- Publication Year 2018-04,Volume 32,Issue #4,Page 1035-1038
- Journal Title
- Leukemia
- Publication Type
- Journal Article
- Publisher
- Springer Nature
- Research Division(s)
- Cancer And Haematology
- PubMed ID
- 29263442
- Publisher's Version
- https://doi.org/10.1038/leu.2017.330
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2019-02-05 08:28:50
Last Modified: 2019-02-05 08:51:02